Navigation Links
Duane Reade Holdings, Inc. Announces Pricing of Offering of 11.75% Senior Secured Notes Due 2015
Date:7/31/2009

NEW YORK, July 31 /PRNewswire/ -- Duane Reade Holdings, Inc. announced today that its wholly-owned subsidiaries, Duane Reade Inc. and Duane Reade (collectively, the "Issuers"), had priced their offering of $300,000,000 aggregate principal amount of Senior Secured Notes due August 1, 2015 (the "Notes"). The Notes will bear interest at an annual rate of 11.75%. The Notes were priced at 97.417%, representing a yield to maturity of 12.375%. The offering of the Notes is expected to close on August 7, 2009.

The Issuers intend to use the net proceeds from the Notes offering, together with a portion of the proceeds from a $125 million preferred equity investment (the "Equity Investment") by entities associated with Oak Hill Capital Partners, L.P., to purchase the Issuers' $210,000,000 aggregate principal amount of Senior Secured Floating Rate Notes due 2010 (the "Floating Rate Notes") and up to $146,250,000 aggregate principal amount of 9.75% Senior Subordinated Notes due 2011 and pay any related consent fees in the Issuers' previously-announced cash tender offer for such securities (collectively, the "Offers") or to optionally redeem any Floating Rate Notes not tendered in the Offers pursuant to an optional redemption notice to be given at the closing date of the offering of the Notes.

The closing of the Notes offering is conditioned upon, among other things, (i) all conditions precedent (including, without limitation, the funding of the Equity Investment) to the Offers, other than the availability of the proceeds of the notes offering, being satisfied or waived and (ii) receipt of an amendment to the Issuers' asset-based revolving loan facility to permit, among other things, the completion of the Offers and the Notes offering.

The offer and sale of the Notes will not be registered under the Securities Act of 1933 and may not be offered or sold in the United States absent such registration or an
'/>"/>

SOURCE Duane Reade Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Duane Reade Holdings, Inc. to Report Third Quarter 2007 Financial Results
2. Duane Reade Holdings, Inc. to Report Fourth Quarter and Full Year 2007 Financial Results
3. Duane Reade Holdings, Inc. Announces Resignation of Chief Marketing Officer
4. Duane Reade Announces Proud Sponsorship of AIDS Walk New York
5. Duane Reade Goes Pink to Support 2008 Komen New York City Race for the Cure(R)
6. Duane Reade Holdings, Inc. Reports Third Quarter Results
7. Duane Reade Holdings, Inc. Further Strengthens Management Team With Addition of Frank Scorpiniti, SVP, Pharmacy Operations
8. Duane Reade Holdings, Inc. Reports Fourth Quarter and Full Year 2008 Results
9. Duane Reade Holdings, Inc. Reports First Quarter 2009 Results
10. Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York
11. Duane Reade Holdings, Inc. Announces Cash Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... beyond, many are looking to private exchanges. “Private ... the August 6 webinar from Atlantic Information Services, will ... insurers’ private exchange strategies for the future. , Barbara ... from PwC with extensive experience in the private exchange ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 According to the ... is a comprehensive guide that will help people get rid ... readers all the necessary information about heartburn and acid reflux. ... truth about heartburn , and risk factors for reflux disease. ... will help people get rid of symptoms of reflux disease ...
(Date:7/28/2014)... 2014 Building a sense of neighborhood ... Where personal outdoor space is not possible, building ... fun and exercise outside is important. That’s why ... quality commercial playground equipment from APCPLAY. , Old Buckingham ... Virginia. It is an historic tourist location of one ...
(Date:7/28/2014)... Los Angeles, Calif., July 27, 2014 - (PRWEB) July 28, ... world title in 12 months by earning the Masters Champion ... July 20, proving that age is no obstacle for this ... and win at the event hosted by the International Pole ... 10 to 63, traveling from 30 countries, took part in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Dr. Alan Xenakis, ... “DOC X MD Funny Feelings.” The new book, DOC ... Feelings in a unique story telling style with humor and ... and motivational. The reader will find answers to those age-old ... running water make people pee? Why do mosquitoes bite some ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2
... doing the rounds that global warming in the East ... A novel research by an international team places ... malaria’s spread, along with other factors like drug and ... University of Michigan theoretical ecologist Mercedes Pascual, has contributed ...
... with danger, is also the color of blood, signaling perpetuation ... of blood on a daily basis to cater to patients ... Sunderland have set the ball rolling, campaigning and urging people ... the run-up to Easter. ,Take the case of ...
... suggests that patients on the newer medications for diabetics ... spent between $920 and $1,760 less on annual total ... lead author and the Merrell Dow professor of pharmacy ... of medical records data on patients who took thiazolidinediones ...
... between widely used childhood medicines and the risk of developing ... allergies, expose the kids to pets and dirt early. The ... is known as the hygiene hypothesis. , It ... fields and farm animals, leaves people more susceptible to a ...
... review of several studies conducted on cancer-causing chemicals has ... babies as a consequence of exposure to organochlorines//. Pesticides ... such chemicals and may be passed on to humans ... it can be indirectly passed on to human beings ...
... cancer is one of the deadliest diseases in UK. Symptoms ... a need to rush to the loo//. ,Hence ... to increase awareness about prostate cancer. Prostate cancer kills 220 ... UK. ,Mr Campbell has won the support ...
Cached Medicine News:Health News:New Diabetic Drugs More Effective than Older Ones 2Health News:A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm 2Health News:Parents Concerned About Pesticide And Cancer Risk To Babies 2
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
(Date:7/28/2014)... and LONDON , July ... Collaboration aims to create and commercialize companion diagnostic using ... of IRESSA  for non-small cell lung cancer patients  ... therascreen   EGFR test and is planned to run on Rotor-Gene Q, ... Project enabled by AstraZeneca master framework agreement adds ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) reported updated ... evaluating QUADRAMET(R) (samarium Sm-153,lexidronam injection) in combination ... with relapsed,multiple myeloma. Data from 33 patients ... 1 Trial of Bortezomib (Vel) and Samarium,(Sam) ...
... achieved with VELCADE, lenalidomide,and dexamethasone , ,KOS, ... (Nasdaq: MLNM) today reported on the,presentation of ... based,therapies that showed consistently high survival and ... newly diagnosed,multiple myeloma (MM) patients. These data ...
Cached Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Phaco chopper delicate rounded tip....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Medicine Products: